Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on...
Trinity Biotech to Announce Q3 2024 Financial Results
Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ETDUBLIN, Ireland, Nov. 14, 2024 -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics,...
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
DUBLIN, Nov. 07, 2024 -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that on November 6, 2024, it received...
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
DUBLIN, Oct. 25, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company...
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
DUBLIN, Oct. 25, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company...
Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology
DUBLIN, Oct. 07, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal...
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women- -The PrePsia test can predict preeclampsia risk as early as in the 12th...
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
DUBLIN, Sept. 18, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on its development and global launch plans...
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
DUBLIN, Ireland, Sept. 09, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its...
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
DUBLIN, Ireland, Sept. 03, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief...